Clinical trial
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and…
NCT00245739 · Tibotec Pharmaceuticals, Ireland, Industry · Approved for marketing
Key facts
| NCT number | NCT00245739 |
|---|---|
| Title | TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. |
| Official title | Early Access of TMC114 in Combination With Low-dose Ritonavir (TMC/r)) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to no Treatment Options. |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | TMC-114 |
| First posted | Oct 28, 2005 |
| Last update posted | Apr 11, 2014 |
| Countries | Belgium, Canada, Czechia, Denmark, Germany, Greece, Hungary, Luxembourg, Malaysia, Mexico, Netherlands, Puerto Rico and 10 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: